Truist analyst Asthika Goonewardene tells investors in a research note that Merus has good data in hand to report at ASCO, with the response rate of 60% putting it in a favorable position based on expectations going in to the abstract. The firm, which made no change to its Buy rating or $69 price target, said the early look on May 28 to discuss the full data, is nothing to be worried about based on feedback from other companies who have done something similar in the past.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
- Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
- Merus granted BTD by the FDA for petosemtamab
- Merus reports Q1 EPS (59c), consensus (81c)
- Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update